Back to top
more

Neogen (NEOG)

(Delayed Data from NSDQ)

$14.44 USD

14.44
1,190,769

+0.16 (1.12%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $14.45 +0.01 (0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (74 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Neogen (NEOG) Gains From Strong Segmental Sales, Innovation

by Zacks Equity Research

Within the biosecurity portfolio, Neogen (NEOG) continues to record solid growth in cleaners, disinfectants and rodenticides.

High Tide Inc. (HITI) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

High Tide Inc. (HITI) delivered earnings and revenue surprises of 25% and 4.52%, respectively, for the quarter ended July 2023. Do the numbers hold clues to what lies ahead for the stock?

Down -12.39% in 4 Weeks, Here's Why Neogen (NEOG) Looks Ripe for a Turnaround

by Zacks Equity Research

Neogen (NEOG) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Neogen (NEOG) Launches SureKill Evolve SC Pest Management Tool

by Zacks Equity Research

Neogen (NEOG) introduces the latest solution in the SureKill brand of products, SureKill Evolve SC.

Here's Why You Should Invest in Neogen (NEOG) Stock Now

by Zacks Equity Research

Investors are optimistic about Neogen (NEOG) on recent product launches.

Is SPDR S&P Health Care Equipment ETF (XHE) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for XHE

Neogen (NEOG) Introduces New Genomic Data Management Tool

by Zacks Equity Research

Neogen's (NEOG) new Igenity Enhanced Dairy offers farmers valid data and assesses their herd's potential. It helps them make the most informed decisions.

Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?

by Zacks Equity Research

Sector ETF report for XHE

Indrajit Bandyopadhyay headshot

3 Medical Product Stocks Set to Outpace Q2 Earnings Estimates

by Indrajit Bandyopadhyay

Medical Product companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how NEOG, PDCO and DH are poised ahead of their earnings release.

Neogen (NEOG) Q4 Earnings Beat Estimates, Gross Margin Up

by Zacks Equity Research

Neogen (NEOG) Q4 fiscal 2023 results reflect core growth in both operating segments despite softening market conditions.

Molina (MOH) Q2 Earnings Beat on High Premiums, '23 View Raised

by Zacks Equity Research

Molina Healthcare's (MOH) second-quarter results are aided by increased membership, and Medicaid and Medicare strength.

Neogen (NEOG) Q4 Earnings and Revenues Top Estimates

by Zacks Equity Research

Neogen (NEOG) delivered earnings and revenue surprises of 40% and 6.38%, respectively, for the quarter ended May 2023. Do the numbers hold clues to what lies ahead for the stock?

Philips (PHG) Q2 Earnings Beat Estimates, Revenue Rise Y/Y

by Zacks Equity Research

Philips' (PHG) second-quarter results benefit from robust performances by the Diagnosis & Treatment and the Connected Care businesses.

Earnings Preview: Neogen (NEOG) Q4 Earnings Expected to Decline

by Zacks Equity Research

Neogen (NEOG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Best Momentum Stocks to Buy for July 19th

by Zacks Equity Research

NEOG, OPK and PCOR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 19, 2023.

New Strong Buy Stocks for July 19th

by Zacks Equity Research

SOHO, FUTU, NEOG, OPK and THRX have been added to the Zacks Rank #1 (Strong Buy) List on July 19, 2023.

Shrabana Mukherjee headshot

Buy These 4 Stocks Following New Analyst Coverage

by Shrabana Mukherjee

The recent surge in analyst coverage for stocks such as Beazer Homes (BZH), Seadrill (SDRL), EnerSys (ENS) and Neogen (NEOG) indicates the potential for significant price appreciation in the near term.

What's in Store for Abbott Laboratories (ABT) in Q2 Earnings?

by Zacks Equity Research

The recent FDA approvals and growing customer demand for core therapeutic lines is likely to have driven Abbott's (ABT) Q2 performance.

Will UnitedHealth's (UNH) UnitedHealthcare Unit Aid Q2 Earnings?

by Zacks Equity Research

UnitedHealth's (UNH) second-quarter results are expected to benefit from an increase in UnitedHealthcare's Community & State revenues, as well as the number of people served.

Will High Medical Costs Affect UnitedHealth (UNH) Q2 Earnings?

by Zacks Equity Research

UnitedHealth's (UNH) second-quarter results are likely to reflect growth in memberships and expense levels.

Why You Should Add Humana (HUM) Stock to Your Portfolio Now

by Zacks Equity Research

Humana's (HUM) strength in Individual Medicare Advantage business and state-based contract wins are likely to be major tailwinds.

Cintas (CTAS) to Post Q4 Earnings: Will Cost Woes Mar Results?

by Zacks Equity Research

Cintas' (CTAS) Q4 performance is likely to have been hurt by rising costs. However, higher volumes and prices within the Uniform Rental and Facility Services unit are likely to have aided the same.

Here's Why You Should Invest in Neogen (NEOG) Stock Now

by Zacks Equity Research

Investors are upbeat about Neogen (NEOG) owing to strong performance across its Animal Safety and Food Safety segments.

Earnings Estimates Moving Higher for Neogen (NEOG): Time to Buy?

by Zacks Equity Research

Neogen (NEOG) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

What Makes Neogen (NEOG) a New Buy Stock

by Zacks Equity Research

Neogen (NEOG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).